Ads
related to: nash liver disease wikipedia english- Management Information
Discover More Information
On The Patient Site.
- Downloadable Resources
Download Doctor Discussion Guide
And Other Helpful Patient Resources
- Tools And Support
Get Helpful Resources And
Support For Patients.
- Specialist Finder
Search for providers specializing
in management options.
- Patient Ambassador
Register for an event & learn more
from a Nurse Educator.
- Stay Informed
Sign Up For Updates
And Get Helpful Information.
- Management Information
Search results
Results From The WOW.Com Content Network
For people with NASH and end-stage liver disease, liver failure, or liver cancer, liver transplantation is an accepted procedure according to the EASL. [16] People with NASH cirrhosis NASH who are being considered for a liver transplant warrant systematic evaluation for cardiovascular diseases (whether the symptoms are apparent or not). [5]
Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes. [1] There are 2 main types of fatty liver disease (FLD):
Fatty liver disease (FLD), also known as hepatic steatosis and steatotic liver disease (SLD), is a condition where excess fat builds up in the liver. [1] Often there are no or few symptoms. [ 1 ] [ 2 ] Occasionally there may be tiredness or pain in the upper right side of the abdomen . [ 1 ]
Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, chronic liver failure or chronic hepatic failure and end-stage liver disease, is a condition of the liver in which the normal functioning tissue, or parenchyma, is replaced with scar tissue and regenerative nodules as a result of chronic liver disease.
Liver diseases, including conditions such as non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease (ALD), and viral hepatitis, are significant public health concerns worldwide. In the United States, NAFLD is the most common chronic liver condition, affecting approximately 24% of the population, with the prevalence rising due ...
Non-alcoholic steatohepatitis (NASH) is projected to become the top reason for liver transplantation in the United States by 2020, supplanting chronic liver disease due to hepatitis C. [137] About 20–45% of the U.S. population have NAFLD and 6% have NASH.
AZD2693 is an antisense therapy developed by AstraZeneca for the treatment of non-alcoholic fatty liver disease based on the PNPLA3 gene, believed to be the largest single genetic risk factor for this condition. [1] [2] [3] [4]
Non-alcoholic steatohepatitis is a common cause of abnormal liver function with histological features of fatty liver, inflammation and fibrosis. It may progress to cirrhosis and is becoming an increasing indication for liver transplantation. It is increasing in prevalence. OCA is proposed to treat NASH. [21]
Ads
related to: nash liver disease wikipedia english